| __timestamp | Supernus Pharmaceuticals, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5758000 | 18516000 |
| Thursday, January 1, 2015 | 8423000 | 34140000 |
| Friday, January 1, 2016 | 11986000 | 51872000 |
| Sunday, January 1, 2017 | 15215000 | 71772000 |
| Monday, January 1, 2018 | 15356000 | 97501000 |
| Tuesday, January 1, 2019 | 16660000 | 118590000 |
| Wednesday, January 1, 2020 | 52459000 | 169802000 |
| Friday, January 1, 2021 | 75061000 | 7491000 |
| Saturday, January 1, 2022 | 87221000 | 8799000 |
| Sunday, January 1, 2023 | 83779000 | 253598000 |
Unlocking the unknown
In the ever-evolving pharmaceutical landscape, understanding cost dynamics is crucial. From 2014 to 2023, Supernus Pharmaceuticals, Inc. and Xencor, Inc. have shown distinct trajectories in their cost of revenue. Supernus Pharmaceuticals started with a modest cost of revenue, peaking in 2022 with a 1,414% increase from 2014. Meanwhile, Xencor, Inc. experienced a more volatile journey, with a staggering 1,270% rise by 2023, despite a dip in 2021. This data highlights the strategic financial maneuvers each company has undertaken to manage production costs amidst market challenges. The contrasting trends underscore the diverse approaches in the pharmaceutical sector, offering insights into how companies adapt to economic pressures and innovation demands. As the industry continues to grow, these insights provide a window into the financial health and strategic priorities of leading pharmaceutical firms.
Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.
Biogen Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Jazz Pharmaceuticals plc and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Cytokinetics, Incorporated vs Xencor, Inc.
Cost of Revenue Trends: ADMA Biologics, Inc. vs Supernus Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: CRISPR Therapeutics AG vs Xencor, Inc.
Cost of Revenue Comparison: Xenon Pharmaceuticals Inc. vs Xencor, Inc.
Analyzing Cost of Revenue: ACADIA Pharmaceuticals Inc. and Xencor, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.'s Expenses
Xencor, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored